Business Context and Reporting Period
Unicycive Therapeutics, Inc. filed a Form 8-K reporting a Nasdaq continued-listing deficiency. The earliest reported event occurred on May 17, 2023; the filing was signed on May 23, 2023.
Key Financial Metrics and Liquidity
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial statement metrics.
Material Change Versus Prior Period
Nasdaq notified the Company that its common stock had closed below the $35 million minimum market value requirement under Nasdaq Listing Rule 5550(b)(2) for 30 consecutive business days. The notice did not immediately affect the listing or trading of the common stock on the Nasdaq Capital Market.
Outlook, Risks, and Contingencies
- The Company received an initial 180-calendar-day compliance period, ending November 13, 2023, to regain compliance.
- If compliance was not regained by that date, Nasdaq stated that the common stock would be subject to a delisting notification.
- The Company indicated that it would monitor its market value and evaluate available options to regain compliance.
- The filing states that there is no assurance the Company will regain compliance or maintain compliance with other Nasdaq Capital Market listing requirements.
- If Nasdaq issued a delisting determination, the Company could appeal the decision to a Nasdaq Hearings Panel.
Facts Investors Should Verify
- Whether the Company regained compliance with the $35 million minimum market value requirement by November 13, 2023.
- Whether Nasdaq issued any subsequent deficiency, delisting, extension, or appeal-related notices.
- Whether the Company took corporate or financing actions that affected its market value or Nasdaq compliance.
- Current compliance with all other Nasdaq Capital Market listing requirements.